Medtronic plc (MDT) earnings on June 3, 2026
Prior outlook: Optimistic
Volatly's outlook before the earnings on June 3, 2026: Optimistic.
MDT price around the earnings
77.95
Change: +4.1%
2026-06-03, 20:00 UTC
Start of the measured window
End of the measured window
73.38
75.25
77.12
78.99
74.85
June 3, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Optimistic
- Thesis published
Context analyzed before publication
- Summary
- Analysts point to an optimistic scenario, but risks remain.
- Reasoning
- Analysts point to an optimistic scenario due to recent company purchases, but recent price drops and mixed past performance raise concerns about execution.
- Playbook
- The scenario suggests clearer signs of positive price movement before investing. Analyst sentiment and company acquisition performance are key factors.
- Trend
- Stock price fell despite analyst optimism.
Analysts
Drivers
-
Analysts
Negative
Some major analysts have recently lowered their ratings to neutral, suggesting growing caution.
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.93
- Analysts covering the stock
- 25
- Average price target
- 106.56
- Lowest price target
- 84
- Highest price target
- 121
- Upside to price target
- 44.5%
- Quarterly earnings growth
- -11.7%
- Revenue growth
- 8.7%
- Forward EPS
- 6.06
- Trailing EPS
- 3.58
- Analyst moves in the last 60 days
- 7
- Strong buy: 2
- Buy: 15
- Hold: 13
- Sell: 0
- Strong sell: 0
- Strong buy
- 2
- Buy
- 15
- Hold
- 13
- Sell
- 0
- Strong sell
- 0
- April 22, 2026 · UBS: Maintains rating (Neutral → Neutral)
- April 15, 2026 · Truist Securities: Maintains rating (Hold → Hold)
- April 13, 2026 · Mizuho: Maintains rating (Outperform → Outperform)
- April 9, 2026 · Evercore ISI Group: Maintains rating (Outperform → Outperform)
- April 7, 2026 · Citigroup: Maintains rating (Buy → Buy)
- April 6, 2026 · Evercore ISI Group: Maintains rating (Outperform → Outperform)
- April 6, 2026 · Argus Research: Maintains rating (Buy → Buy)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (4)
- Medtronic to Report Fiscal Fourth Quarter Results; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call — Benzinga
- Medtronic To Acquire Maker Of Peripheral Nerve Stimulation Therapies SPR Therapeutics For $650M In Cash — Benzinga
- Orchestra BioMed Plans To Complete Enrollment In Its BACKBEAT Study Of Atrioventricular Interval Modulation Therapy By End Of Q3; Plans To Submit Primary Endpoint Data With Medtronic In Q2 — Benzinga
- Orchestra BioMed Receives $20M Investment From Medtronic Under Previously Announced Strategic Financing Agreement — Benzinga
Technicals
Drivers
-
Technical
Negative
The stock's price trend is currently weak, showing significant declines over the past month.
Evidence
- Average true range (ATR)
- 2.1%
- Distance to 52-week high
- -30.6%
- 14-day change (14d)
- -4.0%
- 30-day change (30d)
- -13.3%
- 30-day relative strength
- -13.3%
- Benchmark change (0d)
- +0.0%
- Nearest support
- 73.7
- Nearest resistance
- 74.31
- Volume accumulation ratio (14d / 46d)
- 1.38
Trends
Evidence
- Average earnings surprise
- -6.4%
- February 17, 2026: actual EPS 1.36 vs estimate 1.34 (surprise +1.9%)
- November 18, 2025: actual EPS 1.36 vs estimate 1.31 (surprise +3.5%)
- August 19, 2025: actual EPS 1.26 vs estimate 1.23 (surprise +2.5%)
- May 21, 2025: actual EPS 0.82 vs estimate 1.23 (surprise -33.5%)
Expected move
Drivers
-
Past earnings
Neutral
While the company has often met or exceeded earnings expectations, there have been notable misses in the past.
There is no implied-move data available for this event.
Reactions over its last 19 earnings
- Median move
- 3.1%
- 75th percentile move
- 4.6%
- 90th percentile move
- 5.4%
- Up / down moves
- 8 / 11
- Average up move
- +2.7%
- Average down move
- -4.2%
Monitoring and close
What Medtronic plc reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.